The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice
Official Title: Retrospective Observational Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice
Study ID: NCT02655159
Brief Summary: This is a national, multicenter, retrospective, observational post-authorization study (EPA-OD) study. The study will be conducted by reviewing the medical records of patients up to the start of the study. In each case, only data from before the start of the study will be obtained in order to ensure they are retrospective in nature, thus reflecting the regular use of nab-paclitaxel in clinical practice and avoiding interference with the physician's clinical practice. To ensure the observational nature of this study, these data will be collected whenever they are available in the patient's medical record, and so no diagnostic or therapeutic intervention outside regular clinical practice will be used.
Detailed Description: This is a national, multicenter, retrospective, observational post-authorization study (EPA-OD) study. Investigators will include all consecutive adult patients diagnosed with HER2-negative MBC who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease during the past 3 years (2012-2014). These patients must meet all the inclusion criteria and none of the exclusion criteria established in this protocol. The primary objective is to describe the effectiveness of nab-paclitaxel in terms of response in early lines of chemotherapy for metastatic breast cancer in routine clinical practice. This study plans to collect data retrospectively, provided they are available in the patient's medical record and according to routine clinical practice.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Complejo Hospitalario Jaén, Jaén, Andalucía, Spain
Hospital Clínico Lozano Blesa, Zaragoza, Aragón, Spain
Hospital Virgen Salud, Toledo, Castilla La Mancha, Spain
Hospital Universitario Burgos, Burgos, Castilla y León, Spain
Hospital Clínico Salamanca, Salamanca, Castilla y León, Spain
Hospital Clínico Valladolid, Valladolid, Castilla y León, Spain
Hospital Vall d´Hebron, Barcelona, Cataluña, Spain
Hospital Universitario San Joan Reus, Reus, Cataluña, Spain
Hospital Infanta Cristina, Badajoz, Extremadura, Spain
Capio Clideba, Badajoz, Extremadura, Spain
Complejo Hospitalario Orense, Orense, Galicia, Spain
Hospital Santa Lucía, Cartagena, Murcia, Spain
Hospital Navarra, Pamplona, Navarra, Spain
Hospital Gregorio Marañón, Madrid, , Spain
MD Anderson, Madrid, , Spain
Hospital Clínico San Carlos, Madrid, , Spain
Hospital 12 octubre, Madrid, , Spain
Hospital Quirón, Madrid, , Spain
Hospital Morales Meseguer, Murcia, , Spain
Name: Lorena Pellín, MD
Affiliation: Celgene Spain
Role: STUDY_DIRECTOR